Worm.com

Guide to Spyware and AntiVirus Information

You are currently browsing the Worm.com weblog archives for the day Tuesday, June 3rd, 2008.

 

Sponsors

Archive for June 3rd, 2008

Fortinet® — the pioneer and leading
provider of unified threat management (UTM) solutions — today announced
the top 10 most reported high-risk threats for May 2008. The strongest
development of the month showed adware Vapsup flooding users with
advertisements for rogue virus protection software. Vapsup jumped 42
positions to land on the second spot, just .01 percent behind persistent
malware leader, Netsky. From using plug-ins that hi-jack control of users’
Web browser navigation to rogue antivirus scanner pop-ups, Vapsup had a
bagful of tricks and scare tactics to lure the unsuspecting user into
clicking affiliate links. The incentive for all this trickery was the
per-click payouts through affiliate marketing programs linking back to
servers located mostly in Russia and the U.S.

“Judging by the high level of activity by Vapsup in the past month, the
cyber criminals behind this adware should be getting a huge payday,” said
Derek Manky, security researcher for Fortinet.

Fortinet’s FortiGuard(TM) Global Security Research Team compiled this
report based on intelligence gathered from FortiGate(TM) multi-threat
security systems in production worldwide. Customers who use Fortinet’s
FortiGuard Subscription Services are already protected against the threats
outlined in this report.

Additional malware trends observed during this period include the
following:

--  Online gaming Trojan activity continues in Asia, still concentrated in
    Taiwan and China;
--  An Iframe injection campaign runs strong through Iframe.DN, pointing
    to Korean servers;
--  Parasitic file infector, Virut.A, which made itself known in March
    remains in the top five for three consecutive months, showing longevity.
    

Following are the Top Ten individual threats and Top Five threat families
in May. Top 100 shifts indicate positional changes compared to April’s Top
100 ranking, with “new” representing the malware’s debut in the Top 100.

Top Ten Individual Threats
                                                        % of     Top 100
Rank   Threat Name                      Threat Type  Detections   Shift
1      W32/Netsky!similar               Mass mailer     8.18       -
2      Adware/Vapsup                    Adware          8.17       +42
3      HTML/Iframe_CID!exploit          Exploit         6.25       -
4      W32/Virut.A                      Virus           5.05       +1
5      W32/Pushdo.EV@mm                 Trojan          3.49       new
6      W32/OnLineGamesEncPK.fam!tr.pws  Trojan          2.35       -
7      HTML/Iframe.DN!tr.dldr           Trojan          1.99       +7
8      W32/MyTob.BH.fam@mm              Mass mailer     1.99       -
9      W32/OnLineGames.ADRE!tr.pws      Trojan          1.72       new
10     W32/Zafi.E@mm                    Mass mailer     1.65       +8

Top Five Families

Rank   Malware Family    Percentage   Top 10 Shift
1      Netsky            14.0              -
2      MyTob             8.0               -
3      Virut             5.5               +1
4      Pushdo            3.7               +1
5      MyDoom            2.5               +1

To read the full May report, please visit:
http://www.fortiguardcenter.com/reports/roundup_may_2008.html . For ongoing
threat research, bookmark the FortiGuard Center
( http://www.fortiguardcenter.com/ ) or add it to your RSS feed by going to
http://www.fortinet.com/FortiGuardCenter/rss/index.html . To learn more
about FortiGuard Subscription Services, visit
http://www.fortinet.com/products/fortiguard.html .

FortiGuard Subscription Services offer broad security solutions including
antivirus, intrusion prevention, Web content filtering and anti-spam
capabilities. These services enable protection against threats on both
application and network layers. FortiGuard Services are continuously
updated by the FortiGuard Global Security Research Team, which enables
Fortinet to deliver a combination of multi-layered security intelligence
and true zero-day protection from new and emerging threats. These updates
are delivered to all FortiGate, FortiMail and FortiClient products.

About Fortinet ( www.fortinet.com )

Fortinet is the pioneer and leading provider of ASIC-accelerated unified
threat management, or UTM, security systems, which are used by enterprises
and service providers to increase their security while reducing total
operating costs. Fortinet solutions were built from the ground up to
integrate multiple levels of security protection — including firewall,
antivirus, intrusion prevention, VPN, spyware prevention and anti-spam –
designed to help customers protect against network and content level
threats. Leveraging a custom ASIC and unified interface, Fortinet solutions
offer advanced security functionality that scales from remote office to
chassis-based solutions with integrated management and reporting. Fortinet
solutions have won multiple awards around the world and are the only
security products that are certified in seven programs by ICSA Labs:
(Firewall, Antivirus, IPSec, SSL, Network IPS, and Anti-Spyware). Fortinet
is privately held and based in Sunnyvale, California.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

SAN DIEGO — Aethlon Medical, Inc. (OTCBB:AEMD) announced today that the Aethlon Hemopurifier([R])has proven effective in capturing the reconstructed Spanish Flu of 1918 virus (1918rv). During in vitro testing, high concentrations of 1918rv were rapidly depleted from cell culture fluid when circulated through the Hemopurifier[R]. The study documented that 76 percent of 1918rv was removed from circulation during the first two hours, and by the end of the sixth hour, 93 percent of 1918rv was cleared from circulation. The study data was quantified by reverse transcription polymerase chain reaction (PCR). The Spanish Flu of 1918 is believed to have caused 40-50 million deaths during a two-year time span. The Hemopurifier[R] has also demonstrated effectiveness in capturing H5N1 avian influenza (bird flu). As previously disclosed, the Hemopurifier[R] removed up to 99.4 percent of infectious H5N1 virus from cell culture fluids during a six-hour testing period. Scientists are increasingly worried that H5N1 avian flu could mutate into a strain that triggers a global pandemic that rivals the Spanish Flu of 1918.

"Data against history’s most lethal form of influenza and the looming H5N1 threat validates the Hemopurifier[R] as an innovative strategy to address current and future pandemic flu threats," stated Aethlon chairman and CEO, James A. Joyce. "The data is especially timely, as scientists have discovered that H5N1 virus has emerged to be resistant to the globally stockpiled drug Tamiflu," concluded Joyce.

The May 15, 2008 issue of the science journal Nature reported that researchers have confirmed that H5N1 avian influenza virus has mutated to become resistant to Tamiflu. As per the recommendation of the World Health Organization (WHO), Tamiflu is an antiviral drug agent that has been stockpiled by governments around the world as a potential treatment against pandemic influenza. Researchers now believe that viral mutation will necessitate a multi-pronged treatment approach against future flu pandemics, as antiviral drugs are unlikely to provide clinical benefit as stand-alone therapies. The Hemopurifier[R] holds promise to enhance the benefit of stockpiled drugs and future candidate therapies by clearing the viral strains from circulation that cause drug and vaccine resistance.

The Hemopurifier[R] is a broad-spectrum therapeutic device able to separate and then capture circulating viruses by glycoproteins that reside on their surface. In the case of pandemic influenza, the Hemopurifier[R] is able to separate and then capture circulating influenza virus by hemagglutinin (HA) and neuraminidase (NA) glycoproteins that reside on the virus surface regardless of mutation. As a result, the potential applications of the Hemopurifier[R] against pandemic influenza include:

* The Hemopurifier[R] is a first-line countermeasure against highly virulent strains of pandemic influenza that are untreatable with drug and vaccine therapies.

* The Hemopurifier[R] is an adjunct therapy that captures mutant strains of circulating influenza virus to strengthen the clinical benefit of candidate therapies, including stockpiled countermeasures that are unable to demonstrate treatment effectiveness in advance of a pandemic outbreak.

* The Hemopurifier[R] assists in the initial identification of emerging influenza strains through the concentration and capture of pandemic influenza viruses from the entire circulatory system of infected patients, thus directing the development of candidate drug and vaccine therapies towards the strain of influenza virus that sparks widespread infection.

* The Hemopurifier[R] may also address the needs of immunocompromised and at-risk populations, including children, pregnant women, and senior citizens for whom the administration of drugs or vaccines developed against pandemic influenza may be medically contraindicated.

The reconstructed 1918 influenza virus tested in Hemopurifier[R] in vitro studies, and depicted as 1918rv in this disclosure, was a recombinant virus with two genes (the HA and NA) from the 1918 strain of influenza along with six genes from the Texas 91 influenza strain. The resulting research virus is known as 1918 HA/NA:TX/36/91 in scientific literature. It is anticipated that the use of the Hemopurifier[R] will be directed only towards pandemic strains of influenza whose virulence is attributed by survival and spread in the circulatory system of infected patients. This does not preclude the use of the Hemopurifier[R] as a broad-spectrum countermeasure against other infectious disease and cancer treatment targets.

About Aethlon Medical

Aethlon Medical is the developer of the Hemopurifier[R], a first-in-class medical device designed to treat infectious disease. The Hemopurifier[R] provides real-time therapeutic filtration of infectious viruses and immunosuppressive particles, and is positioned to address the treatment of drug and vaccine resistant viruses. Additionally, the device holds promise in cancer care, as research studies have verified the Hemopurifier[R] is able to capture immunosuppressive particles secreted by tumors. The Hemopurifier[R] is designed to act both as a stand-alone therapeutic, and as an adjunct treatment to enhance clinical benefit of established therapies. Pre-clinical studies conducted by researchers representing leading government and non-government health organizations both in the United States and abroad have documented the effectiveness of the Hemopurifier[R] in capturing from circulation the viruses that constitute pandemic threats, including H5N1 Avian Influenza (bird flu), and Dengue Hemorrhagic Fever (DHF) from circulation. The company is conducting studies to support the use of the Hemopurifier[R] as a broad-spectrum treatment countermeasure against bioterror threats, including Smallpox, and Ebola, Marburg, and Lassa hemorrhagic fever. Regulatory and commercialization initiatives in the United States are presently focused on bioterror threats, while international initiatives are directed toward naturally evolving pandemic threats, and chronic infectious disease conditions including the Human Immunodeficiency Virus (HIV) and Hepatitis-C (HCV). Aethlon demonstrated the safety of the Hemopurifier[R] in a 24-treatment human study at the Apollo Hospital in Delhi, India, and is currently conducting further human studies at the Fortis Hospital, also located in Delhi. The company has submitted an investigational device exemption (IDE) to the U.S. Food and Drug Administration (FDA) to advance the Hemopurifier([R])as a broad-spectrum treatment countermeasure against category "A" bioterror threats. Additional information regarding Aethlon Medical and its Hemopurifier([R]) technology is available online at www.aethlonmedical.com.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

NEW YORK, June 3 /PRNewswire-FirstCall/ — Immtech Pharmaceuticals, Inc. announced today positive results against the hepatitis C virus (HCV) of a compound from its drug discovery portfolio. The prototype compound belongs to an expanding class of compounds that has previously demonstrated activity against a related surrogate virus, bovine viral diarrhea virus (BVDV). The compound was found to have significant activity against HCV under assay conditions designed to demonstrate inhibition of the virus entry process, using a newly available in vitro cell culture system that employs infectious and replicating virus.

Norman Abood, Ph.D., Sr. Vice President, Discovery Programs, stated, "We aim to develop a compound with a novel mechanism of action that is complementary to the currently recognized treatments of HCV. It appears that Immtech’s class of compounds inhibits an early, non-replicative step in the virus life cycle, based upon our earlier work in BVDV. The majority of the industry’s efforts have focused on programs to identify drug candidates, such as protease and polymerase inhibitors, which inhibit HCV virus replication. Our latest findings provide an approach that will allow us to potentially identify a drug candidate with a new and complementary mechanism of action."

As of 2005 there were more than 11 million people living with hepatitis C in major markets around the world, and the sale of drugs to treat the disease, including treatments that are prescribed after a first course of treatment fails, was $3 billion. The HCV drug market is expected to expand to $9 billion in 2012 and to more than $10 billion annually by 2014.

About Immtech Pharmaceuticals, Inc.

Immtech is a pharmaceutical company focused on the development and commercialization of new drugs to treat infectious diseases. Immtech has a well defined, expanding library of compounds targeting Hepatitis C, drug-resistant Gram-positive bacteria, fungal infections and other serious diseases. It is expanding its targeted markets by applying its proprietary pharmaceutical platform to treat a range of disorders. Immtech holds exclusive worldwide licenses to certain patents, patent applications and technology for products derived from its proprietary pharmaceutical platform. For additional information, please visit the Company’s website at http://www.immtechpharma.com/

This press release contains "forward-looking statements" regarding Immtech Pharmaceuticals, Inc.’s business. Except for historical information, the matters discussed in this press release are "forward-looking statements" and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the following: (i) Immtech’s ability to develop commercially viable products; (ii) Immtech’s ability to achieve profitability; (iii) Immtech’s ability to retain key personnel; (iv) the ability of Immtech’s scientists and collaborators to discover new compounds; (v) the availability of additional research grants; (vi) Immtech’s ability to obtain regulatory approval of its drug candidates; (vii) the success of Immtech’s clinical trials; (viii) dependence upon and contractual relationship with partners; (ix) Immtech’s ability to manufacture or to contract with a third party to manufacture its drug candidates at a reasonable cost; (x) Immtech’s ability to protect its intellectual property; (xi) competition and alternative technologies; (xii) Immtech’s ability to obtain reimbursement from third party payers for any product it commercializes; and (xiii) potential exposure to significant product liability.

Additional risks are discussed in the Company’s current filings with the Securities and Exchange Commission. Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT: Media, Bill Berry, of Berry & Co., +1-212-253-8881; or Sean Collins, CCG, +1-310-477-9800, ext. 202, both for Immtech Pharmaceuticals, Inc.

Web site: http://www.immtechpharma.com/

COPYRIGHT 2008 PR Newswire Association LLC
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

SINGAPORE (AFP) — A US pharmaceutical firm is working on a vaccine for dengue fever with the potential to neutralise all four strains of the virus that cause the disease, its chief executive said Tuesday.

Clinical trials of the vaccine will begin in early 2009 in the United States with India and Southeast Asia slated to be the sites for further tests, said Dan Stinchcomb of Inviragen.

“We are focusing on trying to develop a dengue vaccine that can generate very good responses after just one or two doses and we think that this a key to success in this area,” he said on the sidelines of the World Vaccine Congress Asia, an industry gathering.

“We plan to start on human testing next year but even then if all goes well, it won’t be till 2013 or so that we can have a vaccine that can be marketed in Southeast …


Read the full article with a Free Trial at MyWire.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

Cooperation on Non-GLP Viral Clearance Studies

AUBAGNE, France & GOETTINGEN, Germany & ST. PAUL, Minn. — Sartorius Stedim Biotech (Paris:DIM) has entered into an agreement with WuXi AppTec, Inc., a wholly owned operating subsidiary of WuXi PharmaTech (NYSE:WX), to cooperate on viral clearance studies. Under this agreement, WuXi AppTec will provide the relevant viruses, materials and methodologies to Sartorius Stedim Biotech to employ in conducting non GLP viral clearance testing of its technologies with customer products and for supporting its own research and development activities.

Sartorius Stedim Biotech markets an orthogonal and fully integrated three-step viral clearance technology platform to the biopharmaceutical industry. To further support its customers and to meet anticipated regulatory expectations, Sartorius has built an in-house laboratory for non-GLP viral clearance testing of its technologies.

The cooperation with WuXi AppTec will benefit customers because non-GLP viral clearance testing during early-stage process development will allow Sartorius to recommend the best Viral Clearance Technology option. Sartorius and WuXi AppTec will be using the same viruses, materials and methodologies so that customers can reliably anticipate - at this very early stage - predictive study results of what might be expected from WuXi AppTec’s GLP Viral Clearance testing of the same product as part of the IND process and ultimately the Phase 3 validation process.

Viral clearance studies performed during the early stage of process development often help process decisions and provide information about the viral inactivation or removal mechanism. Major regulatory bodies around the world require that companies demonstrate that their purification process has the ability to clear viruses before the drug product receives marketing authorization.

"Viral clearance studies are gaining more importance at early stage process development and with WuXi AppTec we have found an excellent partner to realize both early stage non-GLP testing at Sartorius and GLP testing at WuXi AppTec," stated Reinhard Vogt, Vice CEO Sales and Marketing and Member of the Board of Sartorius Stedim Biotech.

"We are very pleased to be able to partner with Sartorius Stedim Biotech in offering this unique benefit for biopharmaceutical manufacturers," said WuXi AppTec Vice President Larry Thomas. "It is a perfect fit with our company’s commitment to providing clients with seamless single-source solutions to help shorten the time from initial process development to a successful IND."

Image File:

http://www.sartorius-stedim.com/media/content/press/support/Labora tory.jpg

(Due to its length, this URL may need to be copied/pasted into your Internet browser’s address field. Remove the extra space if one exists.)

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions" on a daily basis. Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs over 2,300 people, and in 2007 generated pro forma sales revenue of 375.9 million euros.

A profile of WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech’s services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: www.wuxipharmatech.com.

WuXi AppTec is a wholly owned operating subsidiary of WuXi PharmaTech and it has three FDA-registered U.S. facilities located in Philadelphia, PA; St. Paul, MN; and Atlanta, GA.

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

A mood of deep pessimism has spread among the international community of AIDS scientists following last year’s trial failure of a promising Merck vaccine. This was only the latest in a series of setbacks in the twenty-year struggle to develop an HIV vaccine.

"The passion for finding an HIV vaccine resonates strongly among small pharma, whose often-overlooked approaches may now take center stage as the search for a viable HIV vaccine continues," says Sylvain Fleury, PhD, Chief Scientific Officer and Director at Mymetics, a vaccine company focused on malaria and the human immunodeficiency virus (HIV/AIDS).

Mymetics’ approach is based on proprietary know-how and key intellectual property in matters of antigen engineering and vaccine design that have enabled the company to engineer an acknowledged vaccine candidate in the fight against HIV/AIDS.

"The failures of the past twenty years provide greater understanding of this complex disease. Each advances vaccine design, which improves our knowledge and may benefit various research fields."

Current drug treatments in HIV focus on slowing or impeding the progress of the virus once it has infected the body’s host cells. According to Dr. Fleury, for decades scientists have pursued vaccines that induce an immune protection during infection events that take place only after HIV transmission, meaning once the HIV has crossed the mucosal tissues and has already infected cells.

"Now, it is becoming more evident that acting on earlier transmission events might improve the chance of blocking or slowing down HIV transmission," says Dr. Fleury.

By pursuing and furthering a mucosa approach, Mymetics focuses on preventing early HIV entry into the organism during the first minutes or hours following exposure to the HIV virus, which may be the key to achieving a viable vaccine.

"The mucosa approach has not yet been widely explored," explains Dr. Fleury, "making Mymetics a pioneer in research that has so far shown very promising pre-clinical results."

The urgency for a vaccine that addresses HIV continues to be in the forefront. According to the World Health Organization, in 2007, about two million people died of AIDS globally, thirty-three million were living with HIV and 2.5 million people were newly infected with the virus. For more information, log onto www.mymetics.com.

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

Compound Emerged from Technology Licensed from Schering-Plough Research Institute

ROCKVILLE, Md., June 3 /PRNewswire-FirstCall/ — ViroDefense Inc today announced that it has chosen to advance a compound licensed to ViroDefense Inc by Schering-Plough Corporation into IND-enabling preclinical studies for the prevention and treatment of poliovirus infections.

Schering-Plough licensed to ViroDefense Inc the exclusive rights for development of a specific compound series for polio indications. The license was provided in exchange for the purchase of compound testing supplies and potential future royalties on sales. Schering-Plough Research Institute had been developing the series for treatment of diseases caused by non-polio enteroviruses, such as the coxsackie viruses. ViroDefense Inc determined in laboratory tests that compounds of the series had promising anti-poliovirus activity.

The licensed compounds belong to the antiviral mechanistic class termed "capsid inhibitors." Compounds of this class inhibit the function of the poliovirus capsid, the outer protein coat of the virus, by integrating into the capsid at a specific site or pocket. By doing so, they prevent virus "uncoating" and the release of the viral RNA from the capsid, thereby blocking the initiation of the viral infection cycle.

The lead anti-poliovirus compound, V-073, has been shown to have potent and broad-spectrum anti-poliovirus specific activity, favorable pharmacologic and pharmacokinetic attributes, and the safety and tolerability profile suitable for its advancement as a preclinical candidate. Consequently, IND- enabling studies will commence with V-073.

"We are grateful to Schering-Plough for their willingness to offer this promising antiviral series for the fight against polio," commented Marc S. Collett, President of ViroDefense Inc. "This is clearly a humanitarian gesture on their part."

"We are very pleased to support ViroDefense in its efforts to address a clear public health need during both the final stages of the polio eradication effort and in the post-eradication era," said Thomas P. Koestler, Ph.D., President of Schering-Plough Research Institute.

Background

The Global Polio Eradication Initiative, launched by the World Health Organization (WHO) in 1988, is approaching its goal and expects to certify the world free of polio in the near future. Protecting the estimated $7 billion, two-decade investment will depend on the policies, defense strategies and emergency response capabilities available during these final stages of eradication and in the post-eradication era. These safeguards must protect against virus re-introduction, and in the event of re-introduction, must rapidly contain, control and eliminate the virus.

In November 2005, the National Research Council (NRC) held a workshop, at the request of the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC), to discuss the role and utility of a polio antiviral drug in the efforts to eradicate poliovirus and in the defense of a polio-free world post-eradication. It was concluded that a polio antiviral drug, used alone or in conjunction with current vaccines, would be useful in the control of polio outbreaks, providing increased response flexibility and improved effectiveness. It was further recommended that drug development begin immediately. Currently, there are no drugs for treatment or prevention of poliovirus disease.

In October 2006, the Task Force for Child Survival and Development proposed that a Poliovirus Antiviral Initiative be established to implement the NRC recommendations. The Advisory Committee on Poliomyelitis Eradication (ACPE) supported the proposal and recommended action. In June 2007, the CDC acted on the ACPE recommendations by contracting the Task Force to facilitate development of effective polio antiviral drugs for global public health applications.

About ViroDefense Inc

ViroDefense Inc is an antiviral research, development and consulting company that advocates for and facilitates development of effective antiviral pharmaceuticals that address global public health threats. ViroDefense Inc is presently focused on development of antiviral drugs for poliomyelitis. Currently, there are no poliovirus antiviral drug products available. ViroDefense INC has offices in the Rockville Innovation Center, located in Rockville, MD, part of the Montgomery County Department of Ec